

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

HCT 116 TP53(-/-)

RRID:CVCL_HD97

Type: Cell Line

Proper Citation

RRID:CVCL_HD97

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_HD97

Proper Citation: RRID:CVCL_HD97

Description: Cell line HCT 116 TP53(-/-) is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Colon carcinoma

Defining Citation: [PMID:19225112](#), [PMID:29045385](#)

Comments: Population: Caucasian.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCT 116 TP53(-/-)

Synonyms: TP53 (-/-) HCT116, HCT116-p53-null, Hct116_p53_knockout

Cross References: cancercellines:CVCL_HD97, GEO:GSM383865, GEO:GSM383866, GEO:GSM384089, GEO:GSM384090, Horizon_Discovery:HD+104-001, Wikidata:Q54881988

ID: CVCL_HD97

Hierarchy: cvcl_0291

Record Creation Time: 20220427T220321+0000

Record Last Update: 20260815T233711+0000

Ratings and Alerts

No rating or validation information has been found for HCT 116 TP53(-/-).

No alerts have been found for HCT 116 TP53(-/-).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Szmyd R, et al. (2025) Homologous recombination promotes non-immunogenic mitotic cell death upon DNA damage. *Nature cell biology*, 27(1), 59.

Alruwaili MM, et al. (2025) A Sequential Triple-Drug Strategy for Selective Targeting of p53-Mutant Cancers. *bioRxiv : the preprint server for biology*.

Alruwaili MM, et al. (2024) A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers. *Cell reports. Medicine*, 5(3), 101434.

Yoshizawa K, et al. (2023) Tetraploidy-linked sensitization to CENP-E inhibition in human cells. *Molecular oncology*.

Hsieh YY, et al. (2023) Repositioning VU-0365114 as a novel microtubule-destabilizing agent for treating cancer and overcoming drug resistance. *Molecular oncology*.

Sannigrahi MK, et al. (2022) HPV E6 regulates therapy responses in oropharyngeal cancer by repressing the PGC-1 β /ERR α axis. *JCI insight*, 7(18).

Castell A, et al. (2022) MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner. *Cancer research communications*, 2(3), 182.

Chen R, et al. (2021) Entosis is induced by ultraviolet radiation. *iScience*, 24(8), 102902.

Braun JA, et al. (2020) Effects of the antifungal agent ciclopirox in HPV-positive cancer cells: Repression of viral E6/E7 oncogene expression and induction of senescence and apoptosis. *International journal of cancer*, 146(2), 461.

Agarwal S, et al. (2020) TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status. *Molecular oncology*, 14(12), 3007.

Chen L, et al. (2020) Metformin mitigates gastrointestinal radiotoxicity and radiosensitises P53 mutation colorectal tumours via optimising autophagy. *British journal of pharmacology*, 177(17), 3991.

Sullivan WJ, et al. (2018) Extracellular Matrix Remodeling Regulates Glucose Metabolism through TXNIP Destabilization. *Cell*, 175(1), 117.

Shtraizent N, et al. (2017) MPI depletion enhances O-GlcNAcylation of p53 and suppresses the Warburg effect. *eLife*, 6.